These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25389355)

  • 21. Injection allergen immunotherapy for asthma.
    Abramson MJ; Puy RM; Weiner JM
    Cochrane Database Syst Rev; 2010 Aug; (8):CD001186. PubMed ID: 20687065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.
    Keles S; Karakoc-Aydiner E; Ozen A; Izgi AG; Tevetoglu A; Akkoc T; Bahceciler NN; Barlan I
    J Allergy Clin Immunol; 2011 Oct; 128(4):808-815.e7. PubMed ID: 21641635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
    Hesse L; Nawijn MC
    Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis of the effect of early subcutaneous specific immunotherapy on the levels of dust mite allergen-specific antibodies and polyunsaturated fatty acid metabolism].
    Li SY; Zheng PY; Zhai YY; Zhang YD; Gan H; Huang HM; Luo WT; Jiang MY; Zhang GZ; Zhong RF; Cheng ZK; Sun SX; Sun BQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Jun; 58(6):778-790. PubMed ID: 38955724
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
    Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
    J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.
    Bussmann C; Maintz L; Hart J; Allam JP; Vrtala S; Chen KW; Bieber T; Thomas WR; Valenta R; Zuberbier T; Sager A; Novak N
    Clin Exp Allergy; 2007 Sep; 37(9):1277-85. PubMed ID: 17845407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Predictive model of curative effect of mite subcutaneous immunotherapy in 5-18 years of age patients with allergic asthma].
    Duan QN; Zhao DY; Yan M; Liu F; Chen MX; Yang LH
    Zhonghua Er Ke Za Zhi; 2022 Apr; 60(4):291-296. PubMed ID: 35385932
    [No Abstract]   [Full Text] [Related]  

  • 28. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite.
    Baris S; Kiykim A; Ozen A; Tulunay A; Karakoc-Aydiner E; Barlan IB
    Allergy; 2014 Feb; 69(2):246-53. PubMed ID: 24180595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy.
    Nelson H; Cartier S; Allen-Ramey F; Lawton S; Calderon MA
    J Allergy Clin Immunol Pract; 2015; 3(2):256-266.e3. PubMed ID: 25609326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One century of allergen-specific immunotherapy for respiratory allergy.
    Incorvaia C; Frati F
    Immunotherapy; 2011 May; 3(5):629-35. PubMed ID: 21554092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma.
    Zhang P; Jia Y; Jing Z; Huang J; Wu H; Sun X
    Pulm Pharmacol Ther; 2023 Feb; 78():102187. PubMed ID: 36603742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allergen immunotherapy for asthma.
    Abramson MJ; Puy RM; Weiner JM
    Cochrane Database Syst Rev; 2003; (4):CD001186. PubMed ID: 14583928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.
    Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA
    Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy.
    Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
    Asian Pac J Allergy Immunol; 2013 Sep; 31(3):233-41. PubMed ID: 24053706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of risk factors for systemic adverse reactions to SCIT with natural depot allergen extracts: a retrospective study.
    Asero R
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):211-7. PubMed ID: 26549339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations.
    Cox L; Calderón M; Pfaar O
    Immunotherapy; 2012 Jun; 4(6):601-16. PubMed ID: 22788128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration.
    Antúnez C; Mayorga C; Corzo JL; Jurado A; Torres MJ
    Pediatr Allergy Immunol; 2008 May; 19(3):210-8. PubMed ID: 18399897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.